Drug Trial Radar · NCT07185594
A Phase Ⅱ/Ⅲ Study of HRS-2129 for Postsurgical Pain Management in Abdominal Surgery
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
156
Actual
Start
Oct 24, 2025
Primary completion
Dec 31, 2025
Study completion Jan 30, 2026
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II/III, multi-center, randomized, double-blind, comparator-controlled study to evaluate the efficacy and safety of HRS-2129 for postoperative pain management in abdominal surgery.
Conditions
- Postoperative Analgesia
Interventions
HRS-2129 TabletsDrug
HRS-2129 tablets.
Blank Preparation.Drug
Blank preparation.
Tramadol Hydrochloride SR TabletsDrug
Tramadol Hydrochloride SR tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The time-weighted sum of differences in resting pain intensity within 48 hours after the start of administration of the investigational product.Time frame: Within 48 hours after the start of administration of the investigational product.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.